Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S047 - Inflammatory Skin Diseases: The Translational Revolution

Monday, February 19; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Differentiate Immune Pathways in Inflammatory Skin Diseases.
  • Apply knowledge of underlying mechanisms to novel treatments.
  • Select treatments based on new understanding of disease pathogenesis in inflammatory skin diseases.

Description

In the past decade we experienced a revolution in the mechanistic understanding of inflammatory skin diseases. This translational revolution started with psoriasis, and is now extending to many other common inflammatory skin diseases, and particularly atopic dermatitis, alopecia areata, vitiligo and acne/rosacea. These advances are now translating to rapid development and testing in early and late stage clinical trials of more narrow, targeted treatments for these diseases, that are safer for long-term disease control. In this symposium we will address both the increased understanding and the novel therapeutic developments for inflammatory skin diseases, to ultimately improve patient care.

Disclosures

  • Bissonnette, Robert, MD, MSc: AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Biopharmx – Independent Contractor(Fees); BioPharmX – O(Grants/Research Funding); BMS – A(Fees); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – A(H), I(Grants/Research Funding); Cipher Pharmaceuticals – C(Fees), C(H); Dermira – I(H); Eli Lilly and Company – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding), SP(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding); Xenon Pharmaceuticals – I(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H); Allergan, Inc. – C(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana Biosciences, LLC – C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Dermira – A(H), C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Escalier – C(H); Galderma Research & Development, LLC – A(H), C(H); Glenmark Generics Inc. – B(H), C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding); Medimmune – A(H), C(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); sanofi-aventis – C(H); Sanofi/Regeneron – B(H); Stiefel a GSK company – C(H); Theravance Biopharma – C(H); Vitae Pharmaceuticals – C(H), I(Grants/Research Funding);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); EMD Serono – C(H); Genzyme Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); TeVido Biodevices, LLC – A(SO); Third Rock Ventures – A(H);
  • Krueger, James G., MD, PhD: AbbVie – C(H); Amgen – I(Grants/Research Funding); Baxter – C(H); Biogen – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Delenex Therapeutics AG – C(H); Dermira – C(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); EMD Serono – C(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kadmon Corporation, LLC – C(H), I(Grants/Research Funding); Kineta, Inc. – C(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Merck & Co., Inc. – C(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Parexel – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Provectus Pharmaceuticals – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Sanofi US Services – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding); Xenoport, Inc. – C(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Norris, David Albert, MD: American Skin Association – B(S); Western States Biopharmaceuticals Inc – A(ST);
Schedule
Monday, February 19
9:00 AM
Dr. Guttman / Introduction
9:05 AM
Dr. Lebwohl / An Overview of The Last Decade in Inflammatory Skin Diseases
9:30 AM
Dr. Krueger / Psoriasis: Therapeutic Advances based on increased understanding of disease pathways
9:55 AM
Dr. Guttman / The Translational Revolution in Atopic Dermatitis
10:20 AM
Dr. Norris / Alopecia Areata: Novel Targets and Therapeutics
10:45 AM
Dr. Harris / Vitiligo: New developments
11:10 AM
Dr. Bissonnette / Acne and Rosecea: novel pathogenic and therapeutic developments
11:35 AM
All faculty / Q&A
Event Details
  • Date
    Monday, February 19
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 29D
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
Speakers
  • David Albert Norris, MD, FAAD
  • James G. Krueger, MD, PhD - Handout
  • John Harris, MD, PhD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Robert Bissonnette, MD, MSc, FAAD